Retrospective Cohort Study on Delftia acidovorans Infections in Patients: A Rare and Significant Infection
DOI: https://doi.org/10.2147/idr.s457781
2024-05-06
Infection and Drug Resistance
Abstract:Tsung-Lung Lu, 1 Chienhsiu Huang 2 1 Department of Nursing, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Dalin Town, Chiayi County, Taiwan; 2 Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Dalin Town, Chiayi County, Taiwan Correspondence: Chienhsiu Huang, Department of Internal medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Dalin Town, Chiayi County, Taiwan, Email Background: In recent years, Delftia acidovorans has gained attention for its rare occurrence in patient infections. The literature consists mostly of case reports, necessitating further research to comprehensively understand risk factors, clinical characteristics, and management strategies. Methods: We conducted a retrospective cohort study involving patients diagnosed with Delftia acidovorans infection at a tertiary teaching hospital between January 2014 and December 2022. The data included demographic details, comorbidities, bacterial cultures, antibiotic susceptibility, and treatment outcomes. Results: There were 26 patients diagnosed with Delftia acidovorans infection who were predominantly older with multiple comorbidities. Approximately 76.9% of Delftia acidovorans infection patients had polymicrobial infections. Twenty-one patients had received antibiotics within three months before they developed the Delftia acidovorans infection, and these antibiotics were primarily third-generation cephalosporins, glycopeptides and fluoroquinolones. Antibiotic susceptibility testing showed resistance to aminoglycosides and susceptibility to imipenem, meropenem, ceftazidime, and piperacillin/tazobactam. Treatment outcome showed a mortality rate of 11.5%, mainly in patients with malignancy and advanced age. Conclusion: Delftia acidovorans infections predominantly affect older patients with multiple comorbidities. In terms of antibiotic therapy, carbapenems, cephalosporins, and piperacillin/tazobactam with antipseudomonal activity could all be considered. Keywords: Delftia acidovorans , antibiotic susceptibility, mortality rate The term "Delftia" originates from the city of Delft in the Netherlands, where the type species was first isolated. This nomenclature pays homage to the pioneering contributions of research groups in Delft to the field of bacteriology. In 1987, Pseudomonas acidovorans was reclassified as a Comamonas species based on phenotypic and chemotaxonomic characters, along with DNA‒DNA homology. 1 Later, in 1999, it was renamed Delftia acidovorans ( D. acidovorans ) following 16S rRNA gene sequence analysis after being removed from the Comamonas genus. 2 In recent years, the medical community has become increasingly aware of infrequent infections caused by a diverse array of microbial pathogens. Among these pathogens, D. acidovorans , characterized as a gram-negative, aerobic, nonfermenting, and nonsporeforming rod-shaped bacterium, is commonly found in soil and water environments. Although initially considered nonpathogenic with limited clinical significance, it has gained attention due to its rare occurrence in patient infections. Beyond its environmental habitat, D. acidovorans has been detected in clinical settings, including surgical vacuum manifolds, operating scrub sinks, hemodialysis wall boxes, prime buckets, and reverse osmosis systems. Notably, it exhibits survival within biofilms and displays resistance to various disinfectants, including chlorhexidine. 3 The clinical spectrum of these infections spans from ocular, respiratory, or urinary tract infection to bloodstream infection, peritonitis, and even endocarditis. 4–9 Despite the relatively low incidence of D. acidovorans infections, their impact on affected patients can be substantial. Currently, the understanding of D. acidovorans infection remains limited and is primarily derived from case reports and sporadic retrospective case series studies. Given the paucity of knowledge surrounding the pathogenicity and clinical outcomes associated with D. acidovorans infections, further research is imperative to elucidate risk factors, clinical features, and optimal management strategies for affected patients. To bridge this knowledge gap, we embarked on a retrospective cohort study involving patients diagnosed with D. acidovorans infection at a tertiary teaching hospital between 2014 and 2022. The aim of the study is to elucidate the clinical characteristics and outcomes of these infections. Through a comprehensive analysis of diverse case data, the populations most susceptible to -Abstract Truncated-
pharmacology & pharmacy,infectious diseases